J
7.49
0.17 (2.32%)
市场趋势
短期 | 中期 | ||
行业 | Biotechnology (US) | 混合的 | 看跌 |
Biotechnology (全球的) | 混合的 | 看跌 | |
股票 | Jade Biosciences, Inc. | 看涨 | - |
AIStockmoo 评分
1.6
分析师共识 | 3.0 |
内部交易活动 | NA |
价格波动 | 0.5 |
技术平均移动指标 | 3.5 |
技术振荡指标 | -0.5 |
平均 | 1.63 |
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade’s pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. |
|
部门 | Healthcare |
行业 | Biotechnology |
内部持股比例 | 0.04% |
机构持股比例 | 33.40% |
所有权
姓名 | 日期 | 持有股份 |
---|---|---|
Allostery Investments Lp | 31 Mar 2025 | 40,614 |
Intech Investment Management Llc | 30 Jun 2025 | 22,995 |
52周波幅 | ||
目标价格波幅 | ||
高 | 18.00 (Wedbush, 140.32%) | 购买 |
中 | 16.00 (113.62%) | |
低 | 14.00 (Guggenheim, 86.92%) | 购买 |
平均值 | 16.00 (113.62%) | |
总计 | 2 购买 | |
平均价格@调整类型 | 7.24 |
公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
---|---|---|---|---|
Wedbush | 14 Aug 2025 | 18.00 (140.32%) | 购买 | 7.49 |
Guggenheim | 16 Jun 2025 | 14.00 (86.92%) | 购买 | 6.99 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合